Is Ebglyss Approved for Children with Severe Eczema?
Ebglyss (lebrikizumab-lbkz), an IL-13 inhibitor from Eli Lilly, is FDA-approved for moderate-to-severe atopic dermatitis (severe eczema) in adults and children 12 years and older weighing at least 40 kg (88 lbs). It is not approved for kids under 12 or those below 40 kg.[1][2]
How Was Safety Tested in Children?
Approval for adolescents 12+ came from the ADvocate 2 trial, a phase 3 study with 422 patients aged 12-17. Over 16 weeks, 36% achieved clear or almost clear skin (IGA 0/1) versus 19% on placebo. Common side effects matched adult data: conjunctivitis (10%), injection site reactions (5%), and herpes infections (3%). No new safety signals emerged, and long-term data up to 52 weeks showed consistent tolerability.[1][3]
What Do Real-World Safety Data Show for Kids?
Post-approval monitoring and adolescent trial extensions report low serious adverse event rates (under 5%), mainly mild eye issues resolving without discontinuation. No deaths or anaphylaxis linked to Ebglyss in pediatric cohorts. Eye exams are recommended before and during treatment due to conjunctivitis risk.[2][4]
Why Not for Younger Children Under 12?
No trials support use in kids under 12. Ongoing studies (e.g., NCT04800315) explore efficacy/safety down to 6 months, but results are pending. Off-label use lacks data and isn't recommended.[1][5]
What Side Effects Should Parents Watch For?
Most common (5-10%): eye inflammation, cold sores, yeast infections. Rare: serious eye issues or hypersensitivity. Monitor for vision changes; avoid live vaccines. It's pregnancy category not assigned—discuss risks if relevant.[2][3]
How Does It Compare to Dupixent for Kids?
Dupixent (dupilumab) is approved from 6 months old, with broader pediatric data. Ebglyss targets IL-13 specifically, potentially fewer eye issues long-term, but lacks head-to-head trials. Choice depends on age/weight; Ebglyss offers self-injection convenience.[1][6]
When Might It Expand to Younger Kids?
Eli Lilly plans submissions based on pediatric trials ending 2025. Patent protection lasts until ~2038, per DrugPatentWatch.[7][8]
Sources
[1]: FDA Label for Ebglyss
[2]: Ebglyss HCP Site
[3]: NEJM ADvocate 2 Results
[4]: FDA Postmarketing Surveillance
[5]: ClinicalTrials.gov NCT04800315
[6]: Dupixent Label
[7]: DrugPatentWatch: Ebglyss Patents
[8]: Lilly Pipeline Update